Loading…
Develops targeted oncology therapies including an approved menin inhibitor for genetically defined leukemias.
Develops targeted oncology therapies including an approved menin inhibitor for genetically defined leukemias.
Revuforj, approved in 2024 for relapsed acute leukemia with a certain gene change, is its own product, so sales rest on a small number of specialist cancer centres. Axatilimab, a graft-versus-host disease antibody, is developed and sold in partnership with Incyte.
Moat: narrow (IP / patents, regulatory licence). First approved menin inhibitor for a genetically defined leukemia subtype, with an Incyte GvHD partnership.
Headquarters: Waltham, Massachusetts, US · Founded: 2005 · Employees: 298
Size Syndax Pharmaceuticals (SNDX) is a United States Health Care company (Biotechnology) with a market value of $859M, the 2346th largest of 3,117 United States companies the cockpit tracks. Shares closed at $9.54 on 6 Nov 2026.
Performance Over six months the shares fell 55.6%, against -17.9% for the median peer and -1.1% for the United States market (cap-weighted) — lowest of 19 in its peer set.
Growth Revenue grew 159.7% over the last twelve months (peer median -1.8%); the operating margin is -61.7% (peer median -24.3%).
Valuation It trades at 3.5× enterprise value to sales against a peer median of 7.6× (3rd cheapest of 18).
Capital Return on invested capital runs 103.7 points below its cost of capital (6.5% WACC).
Credit Syndax Pharmaceuticals has 1 bond outstanding ($250M).
Short interest Short interest is 20.2% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $290M | $172M | $23.7M | $0 | $0 |
| Revenue growth | — | +628% | — | — | — |
| Gross profit | $267M | $165M | $22.8M | -$12,000 | -$454,000 |
| EBITDA | -$179M | -$273M | -$340M | -$230M | -$151M |
| Net income | -$209M | -$285M | -$319M | -$209M | -$149M |
| Free cash flow | -$177M | -$323M | -$275M | -$161M | -$134M |
| Capital expenditure | $96,000 | $187,000 | $0 | $0 | $0 |
| Total debt | $589M | $345M | $346M | $1.64M | $1.16M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals SNDX | $859M | -56% | +160% | -62% | 3.5× | n/a |
| Kura Oncology KURA | $647M | -23% | -7% | -412% | 2.0× | n/a |
| Incyte INCY | $24.4B | +21% | +25% | 12% | 3.4× | 14.2% |
| Novartis NOVN.SW | $298B | +15% | -4% | 30% | 6.3× | 1.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SNDX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -43.5% | -5.6% | lowest of 21 |
| 6-month return | -55.6% | -17.9% | lowest of 19 |
| Distance from 52-week high | -62.7% | -42.6% | lowest of 21 |
| Revenue growth (TTM) | +159.7% | -1.8% | 2nd highest of 17 |
| Operating margin | -61.7% | -24.3% | 7th lowest of 18 |
| EV / Sales | 3.5× | 7.6× | 3rd cheapest of 18 |
| ROIC minus cost of capital | -103.7 pp | -13.3 pp | 2nd lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals SNDX | United States | $859M | -56% | +160% | -62% | 3.5× | n/a | n/a |
| Peptidream 4587.T | Japan | $856M | -10% | +1% | -25% | 6.6× | n/a | n/a |
| MeiraGTx MGTX | United States | $864M | -8% | +948% | 46% | 2.1× | -9.9% | +39.2% |
| GNI 2160.T | Japan | $866M | -29% | +10% | -24% | 5.7× | n/a | n/a |
| Prime Medicine PRME | United States | $843M | +45% | -18% | -4,825% | 211.3× | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $892M | -14% | +16% | -18% | 4.3× | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $902M | -45% | -84% | -633% | 11.1× | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $814M | -19% | -22% | 20% | 4.7× | 8.8% | +2.4% |
| Inventiva IVA.PA | France | $912M | -29% | -100% | -307,063% | 14,560.9× | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $803M | -12% | +21% | 11% | 3.9× | 20.1% | +11.8% |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $803M | +91% | -15% | -8% | 17.9× | 48.8% | +14.7% |
| Odyssey Therapeutics ODTX | United States | $924M | n/a | -33% | -5,415% | 208.9× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $927M | -54% | n/a | -108% | 26.5× | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $793M | -21% | -4% | -119% | 7.6× | -12.3% | -10.9% |
| Alphamab Oncology 9966.HK | Hong Kong | $777M | -39% | -32% | -38% | 8.2× | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $777M | n/a | n/a | n/a | n/a | n/a | n/a |
| Jade Biosciences JBIO | United States | $958M | -42% | n/a | n/a | n/a | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $960M | -17% | +1% | 2% | 1.4× | 6.6% | +4.4% |
| Alto Neuroscience ANRO | United States | $987M | +4% | n/a | n/a | n/a | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $746M | -37% | +153% | -20% | 13.1× | 43.2% | +21.5% |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $995M | -11% | 0% | 22% | 4.7× | 11.1% | +2.3% |
Syndax Pharmaceuticals has 1 bond outstanding with $250M face value.